1887

Chapter 110 : Antiviral Agents

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Antiviral Agents, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817381/9781555817381.ch110-1.gif /docserver/preview/fulltext/10.1128/9781555817381/9781555817381.ch110-2.gif

Abstract:

The use of antiviral agents for the treatment of viral diseases has rapidly increased over the past 2 decades. In this chapter, antiviral therapy for the most common, clinically relevant viral infections is reviewed. The chapter is organized by virus type and covers human immunodeficiency virus types 1 and 2 (HIV-1, HIV-2), hepatitis viruses B and C (HBV and HCV), influenza A and B viruses, and the human herpesviruses with a focus on herpes simplex virus, varicella-zoster virus, and human cytomegalovirus. For each virus, an overview of available therapies is provided, followed by an in-depth description of individual antiviral agents. This description includes information on the agent’s chemical structure, mechanism of action, bioavailability, adverse effects, and significant drug interactions. In addition, current treatment guideline recommendations are incorporated when available. References for these guidelines allow for access to future updates to recommended drug therapies. This chapter strives to provide readers with an up-to-date overview of antiviral therapy. Newly approved agents as well as promising agents in the late stages of clinical trials have been included. Specific new additions to this edition include the antiretroviral agent dolutegravir and newly approved directly acting antiviral agents for hepatitis C virus.

Citation: Hodowanec A, Thompson K, Lurain N. 2015. Antiviral Agents, p 1869-1893. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of Clinical Microbiology, Eleventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817381.ch110
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555817381.mcm11.ch110
1. De Clercq E. 2009. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 33:307320.
2. Mould DR,, Zhang X,, Nieforth K,, Salgo M,, Buss N,, Patel IH. 2005. Population pharmacokinetics and exposureresponse relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients. Clin Pharmacol Ther 77:515528.
3. Schmidt AC. 2004. Antiviral therapy for influenza: a clinical and economic comparative review. Drugs 64:20312046.
4. Hicks C,, Gulick RM. 2009. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis 48:931939.
5. Kiser JJ. 2008. Pharmacologic characteristics of investigational and recently approved agents for the treatment of HIV. Curr Opin HIV AIDS 3:330341.
6. Menendez-Arias L,, Tozser J. 2008. HIV-1 protease inhibitors: effects on HIV-2 replication and resistance. Trends Pharmacol Sci 29:4249.
7. Crumpacker CS. 1996. Ganciclovir. N Engl J Med 335: 721729.
8. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf. Accessed 26 January 2015.
9. Panel on Antiretroviral Guidelines for Adults and Adolescents. 2013. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. Available at http://aidsinfo .nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 26 January 2015.
10. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. 2014. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Available at http://aidsinfo.nih.gov/contentfiles/lvguide lines/PerinatalGL.pdf. Accessed 26 January 2015.
11. Younger HM,, Bathgate AJ,, Hayes PC. 2004. Nucleoside analogues for the treatment of chronic hepatitis B. Aliment Pharmacol Ther 20:12111230.
12. Cote HC,, Brumme ZL,, Craib KJ,, Alexander CS,, Wynhoven B,, Ting L,, Wong H,, Harris M,, Harrigan PR,, O’Shaughnessy MV,, Montaner JS. 2002. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 346:811820.
13. Brinkman K,, Smeitink JA,, Romijn JA,, Reiss P. 1999. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354:11121115.
14. Capparelli EV,, Letendre SL,, Ellis RJ,, Patel P,, Holland D,, McCutchan JA. 2005. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob Agents Chemother 49:25042506.
15. Strategies for Management of Anti-Retroviral Therapy/INSIGHT1, DAD Study Groups. 2008. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 22:F17F24.
16. Hsue PY,, Hunt PW,, Wu Y,, Schnell A,, Ho JE,, Hatano H,, Xie Y,, Martin JN,, Ganz P,, Deeks SG. 2009. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 23:20212027.
17. Ribaudo HJ,, Benson CA,, Zheng Y,, Koletar SL,, Collier AC,, Lok JJ,, Smurzynski M,, Bosch RJ,, Bastow B,, Schouten JT. 2011. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis 52:929940.
18. Mallal S,, Phillips E,, Carosi G,, Molina JM,, Workman C,, Tomazic J,, Jagel-Guedes E,, Rugina S,, Kozyrev O,, Cid JF,, Hay P,, Nolan D,, Hughes S,, Hughes A,, Ryan S,, Fitch N,, Thorborn D,, Benbow A. 2008. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 358:568579.
19. Pruvost A,, Negredo E,, Benech H,, Theodoro F,, Puig J,, Grau E,, Garcia E,, Molto J,, Grassi J,, Clotet B. 2005. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 49:19071914.
20. Ray AS,, Olson L,, Fridland A. 2004. Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob Agents Chemother 48:10891095.
21. Tozzi V,, Balestra P,, Salvatori MF,, Vlassi C,, Liuzzi G,, Giancola ML,, Giulianelli M,, Narciso P,, Antinori A. 2009. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr 52:5663.
22. Perry CM. 2009. Emtricitabine/tenofovir disoproxil fumarate: in combination with a protease inhibitor in HIV-1 infection. Drugs 69:843857.
23. Foudraine NA,, Hoetelmans RM,, Lange JM,, de Wolf F,, van Benthem BH,, Maas JJ,, Keet IP,, Portegies P. 1998. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 351:15471551.
24. Havlir DV,, Tierney C,, Friedland GH,, Pollard RB,, Smeaton L,, Sommadossi JP,, Fox L,, Kessler H,, Fife KH,, Richman DD. 2000. In vivo antagonism with zidovudine plus stavudine combination therapy. J Infect Dis 182:321325.
25. Piscitelli SC,, Gallicano KD. 2001. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 344:984996.
26. Gallant JE,, DeJesus E,, Arribas JR,, Pozniak AL,, Gazzard B,, Campo RE,, Lu B,, McColl D,, Chuck S,, Enejosa J,, Toole JJ,, Cheng AK. 2006. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354:251260.
27. Ruane PJ,, Dejesus E,, Berger D,, Markowitz M,, Bredeek UF,, Callebaut C,, Zhong L,, Ramanathan S,, Rhee MS,, Fordyce MW,, Yale K. 2013. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr 63:449455.
28. Fischl MA,, Richman DD,, Grieco MH,, Gottlieb MS,, Volberding PA,, Laskin OL,, Leedom JM,, Groopman JE,, Mildvan D,, Schooley RT, , et al. 1987. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 317:185191.
29. Durand-Gasselin L,, Pruvost A,, Dehee A,, Vaudre G,, Tabone MD,, Grassi J,, Leverger G,, Garbarg-Chenon A,, Benech H,, Dollfus C. 2008. High levels of zidovudine (AZT) and its intracellular phosphate metabolites in AZT- and AZT-lamivudine-treated newborns of human immunodeficiency virus-infected mothers. Antimicrob Agents Chemother 52:25552563.
30. Cimoch PJ,, Lavelle J,, Pollard R,, Griffy KG,, Wong R,, Tarnowski TL,, Casserella S,, Jung D. 1998. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects. J Acquir Immune Defic Syndr Hum Retrovirol 17:227234.
31. Castello G,, Mela G,, Cerruti A,, Mencoboni M,, Lerza R. 1995. Azidothymidine and interferon-alpha in vitro effects on hematopoiesis: protective in vitro activity of IL-1 and GM-CSF. Exp Hematol 23:13671371.
32. Gulick RM,, Ribaudo HJ,, Shikuma CM,, Lustgarten S,, Squires KE,, Meyer WAIII,, Acosta EP,, Schackman BR,, Pilcher CD,, Murphy RL,, Maher WE,, Witt MD,, Reichman RC,, Snyder S,, Klingman KL,, Kuritzkes DR. 2004. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 350:18501861.
33. Walmsley S,, Avihingsanon A,, Slim J,, Ward DJ,, Ruxrungtham K,, Brunetta J,, Bredeek UF,, Jayaweera D,, Guittari CJ,, Larson P,, Schutz M,, Raffi F. 2009. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr 50:367374.
34. Johnson LB,, Saravolatz LD. 2009. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor. Clin Infect Dis 48:11231128.
35. Briz V,, Garrido C,, Poveda E,, Morello J,, Barreiro P,, de Mendoza C,, Soriano V. 2009. Raltegravir and etravirine are active against HIV type 1 group O. AIDS Res Hum Retroviruses 25:225227.
36. Mmiro FA,, Aizire J,, Mwatha AK,, Eshleman SH,, Donnell D,, Fowler MG,, Nakabiito C,, Musoke PM,, Jackson JB,, Guay LA. 2009. Predictors of early and late mother-to-child transmission of HIV in a breastfeeding population: HIV Network for Prevention Trials 012 experience, Kampala, Uganda. J Acquir Immune Defic Syndr 52:3239.
37. Eron JJJr. 2000. HIV-1 protease inhibitors. Clin Infect Dis 30(Suppl 2):S160S170.
38. Koh Y,, Matsumi S,, Das D,, Amano M,, Davis DA,, Li J,, Leschenko S,, Baldridge A,, Shioda T,, Yarchoan R,, Ghosh AK,, Mitsuya H. 2007. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J Biol Chem 282:2870928720.
39. Ford J,, Khoo SH,, Back DJ. 2004. The intracellular pharmacology of antiretroviral protease inhibitors. J Antimicrob Chemother 54:982990.
40. Zeldin RK,, Petruschke RA. 2004. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 53:49.
41. Boffito M,, Maitland D,, Samarasinghe Y,, Pozniak A. 2005. The pharmacokinetics of HIV protease inhibitor combinations. Curr Opin Infect Dis 18:17.
42. Youle M. 2007. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. J Antimicrob Chemother 60:11951205.
43. Cooper CL,, van Heeswijk RP,, Gallicano K,, Cameron DW. 2003. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis 36:15851592.
44. Orrick JJ,, Steinhart CR. 2004. Atazanavir. Ann Pharmacother 38:16641674.
45. Havlir DV,, O’Marro SD. 2004. Atazanavir: new option for treatment of HIV infection. Clin Infect Dis 38:15991604.
46. Wire MB,, Shelton MJ,, Studenberg S. 2006. Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet 45:137168.
47. Fellay J,, Marzolini C,, Decosterd L,, Golay KP,, Baumann P,, Buclin T,, Telenti A,, Eap CB. 2005. Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur J Clin Pharmacol 60:865873.
48. Isaac A,, Taylor S,, Cane P,, Smit E,, Gibbons SE,, White DJ,, Drake SM,, Khoo S,, Back DJ. 2004. Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. J Antimicrob Chemother 54:498502.
49. Yeni P. 2003. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity. J Acquir Immune Defic Syndr 34(Suppl 1):S91S94.
50. Covens K,, Kabeya K,, Schrooten Y,, Dekeersmaeker N,, Van Wijngaerden E,, Vandamme AM,, De Wit S,, Van Laethem K. 2009. Evolution of genotypic resistance to enfuvirtide in HIV-1 isolates from different group M subtypes. J Clin Virol 44:325328.
51. Vandekerckhove L,, Verhofstede C,, Vogelaers D. 2009. Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients. J Antimicrob Chemother 63:10871096.
52. Depatureaux A,, Charpentier C,, Collin G,, Leoz M,, Descamps D,, Vessiere A,, Damond F,, Rousset D,, Brun-Vezinet F,, Plantier JC. 2010. Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide. Antimicrob Agents Chemother 54:40164019.
53. Este JA,, Telenti A. 2007. HIV entry inhibitors. Lancet 370:8188.
54. MacArthur RD,, Novak RM. 2008. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis 47:236241.
55. Lennox JL,, DeJesus E,, Lazzarin A,, Pollard RB,, Madruga JV,, Berger DS,, Zhao J,, Xu X,, Williams-Diaz A,, Rodgers AJ,, Barnard RJ,, Miller MD,, DiNubile MJ,, Nguyen BY,, Leavitt R,, Sklar P. 2009. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 374:796806.
56. Cooper DA,, Steigbigel RT,, Gatell JM,, Rockstroh JK,, Katlama C,, Yeni P,, Lazzarin A,, Clotet B,, Kumar PN,, Eron JE,, Schechter M,, Markowitz M,, Loutfy MR,, Lennox JL,, Zhao J,, Chen J,, Ryan DM,, Rhodes RR,, Killar JA,, Gilde LR,, Strohmaier KM,, Meibohm AR,, Miller MD,, Hazuda DJ,, Nessly ML,, DiNubile MJ,, Isaacs RD,, Teppler H,, Nguyen BY. 2008. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 359:355365.
57. Ramanathan S,, Mathias AA,, German P,, Kearney BP. 2011. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet 50:229244.
58. Arribas JR,, Eron J. 2013. Advances in antiretroviral therapy. Curr Opin HIV AIDS 8:341349.
59. Lepist EI,, Phan TK,, Roy A,, Tong L,, Maclennan K,, Murray B,, Ray AS. 2012. Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob Agents Chemother 56:54095413.
60. Eron JJ,, Clotet B,, Durant J,, Katlama C,, Kumar P,, Lazzarin A,, Poizot-Martin I,, Richmond G,, Soriano V,, Ait-Khaled M,, Fujiwara T,, Huang J,, Min S,, Vavro C,, Yeo J. 2013. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 207:740748.
61. Min S,, Song I,, Borland J,, Chen S,, Lou Y,, Fujiwara T,, Piscitelli SC. 2010. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 54:254258.
62. Cahn P,, Pozniak AL,, Mingrone H,, Shuldyakov A,, Brites C,, Andrade-Villanueva JF,, Richmond G,, Buendia CB,, Fourie J,, Ramgopal M,, Hagins D,, Felizarta F,, Madruga J,, Reuter T,, Newman T,, Small CB,, Lombaard J,, Grinsztejn B,, Dorey D,, Underwood M,, Griffith S,, Min S. 2013. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 382:700708.
63. Gara N,, Ghany MG. 2013. What the infectious disease physician needs to know about pegylated interferon and ribavirin. Clin Infect Dis 56:16291636.
64. Fox AN,, Jacobson IM. 2012. Recent successes and noteworthy future prospects in the treatment of chronic hepatitis C. Clin Infect Dis 55(Suppl 1):S16S24.
65. Laguno M,, Cifuentes C,, Murillas J,, Veloso S,, Larrousse M,, Payeras A,, Bonet L,, Vidal F,, Milinkovic A,, Bassa A,, Villalonga C,, Perez I,, Tural C,, Martinez-Rebollar M,, Calvo M,, Blanco JL,, Martinez E,, Sanchez-Tapias JM,, Gatell JM,, Mallolas J. 2009. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 49:2231.
66. Legrand-Abravanel F,, Nicot F,, Boulestin A,, Sandres-Saune K,, Vinel JP,, Alric L,, Izopet J. 2005. Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. J Med Virol 77:6669.
67. Shire NJ,, Sherman KE. 2005. Clinical trials of treatment for hepatitis C virus infection in HIV-infected patients: past, present, and future. Clin Infect Dis 41(Suppl 1):S63S68.
68. Yee HS,, Chang MF,, Pocha C,, Lim J,, Ross D,, Morgan TR,, Monto A. 2012. Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol 107:669689.
69. American Association for the Study of Liver Disease (AASLD) and the Infectious Diseases Society of America (IDSA). 2015. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/full-report-view. Accessed January 26, 2015.
70. Price RW,, Parham R,, Kroll JL,, Wring SA,, Baker B,, Sailstad J,, Hoh R,, Liegler T,, Spudich S,, Kuritzkes DR,, Deeks SG. 2008. Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin. Antivir Ther 13:369374.
71. Manns MP,, McHutchison JG,, Gordon SC,, Rustgi VK,, Shiffman M,, Reindollar R,, Goodman ZD,, Koury K,, Ling M,, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958965.
72. Ghany MG,, Strader DB,, Thomas DL,, Seeff LB. 2009. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49:13351374.
73. Preston SL,, Drusano GL,, Glue P,, Nash J,, Gupta SK,, McNamara P. 1999. Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob Agents Chemother 43:24512456.
74. Bonney D,, Razali H,, Turner A,, Will A. 2009. Successful treatment of human metapneumovirus pneumonia using combination therapy with intravenous ribavirin and immune globulin. Br J Haematol 145:667669.
75. Liu V,, Dhillon GS,, Weill D. 2010. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. Transpl Infect Dis 12:3844.
76. Mertz GJ,, Miedzinski L,, Goade D,, Pavia AT,, Hjelle B,, Hansbarger CO,, Levy H,, Koster FT,, Baum K,, Lindemulder A,, Wang W,, Riser L,, Fernandez H,, Whitley RJ. 2004. Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin Infect Dis 39:13071313.
77. Nguyen JT,, Hoopes JD,, Smee DF,, Prichard MN,, Driebe EM,, Engelthaler DM,, Le MH,, Keim PS,, Spence RP,, Went GT. 2009. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob Agents Chemother 53:41154126.
78. Smee DF,, Hurst BL,, Wong MH,, Bailey KW,, Morrey JD. 2009. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob Agents Chemother 53:21202128.
79. Patterson JL,, Fernandez-Larsson R. 1990. Molecular mechanisms of action of ribavirin. Rev Infect Dis 12:11391146.
80. Crotty S,, Maag D,, Arnold JJ,, Zhong W,, Lau JY,, Hong Z,, Andino R,, Cameron CE. 2000. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 6:13751379.
81. Leyssen P,, Balzarini J,, De Clercq E,, Neyts J. 2005. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol 79:19431947.
82. Perronne C. 2006. Antiviral hepatitis and antiretroviral drug interactions. J Hepatol 44:S119S125.
83. Pawlotsky JM. 2013. NS5A inhibitors in the treatment of hepatitis C. J Hepatol 59:375382.
84. Smith MA,, Chan J,, Mohammad RA. 2014. Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection. Ann Pharmacother pii: 1060028014563952 [Epub ahead of print].
85. Koff RS. 2014. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 39:478487.
86. AbbVie Inc. 2014. Viekira Pak (ombitasvir/paritaprevir/ritonavir; dasabuvir) prescribing information. AbbVie Inc, North Chicago, IL.
87. BioCryst Pharmaceuticals. 2014. Rapivab (peramivir) prescribing information. BioCryst Pharmaceuticals, Durham, NC.
88. Gish RG,, Trinh H,, Leung N,, Chan FK,, Fried MW,, Wright TL,, Wang C,, Anderson J,, Mondou E,, Snow A,, Sorbel J,, Rousseau F,, Corey L. 2005. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J Hepatol 43:6066.
89. Soriano V,, Puoti M,, Bonacini M,, Brook G,, Cargnel A,, Rockstroh J,, Thio C,, Benhamou Y. 2005. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV international panel. AIDS 19:221240.
90. Fontana RJ. 2009. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 49:S185S195.
91. Soriano V,, Puoti M,, Peters M,, Benhamou Y,, Sulkowski M,, Zoulim F,, Mauss S,, Rockstroh J. 2008. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 22:13991410.
92. Mohanty SR,, Cotler SJ. 2005. Management of hepatitis B in liver transplant patients. J Clin Gastroenterol 39:5863.
93. Levrero M,, Pollicino T,, Petersen J,, Belloni L,, Raimondo G,, Dandri M. 2009. Control of cccDNA function in hepatitis B virus infection. J Hepatol 51:581592.
94. Erhardt A,, Blondin D,, Hauck K,, Sagir A,, Kohnle T,, Heintges T,, Haussinger D. 2005. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 54:10091013.
95. Wai CT,, Chu CJ,, Hussain M,, Lok AS. 2002. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 36:14251430.
96. Kaplan JE,, Benson C,, Holmes KH,, Brooks JT,, Pau A,, Masur H. 2009. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recommend Rep 58:1207; quiz, CE1–4.
97. van Bommel F,, Zollner B,, Sarrazin C,, Spengler U,, Huppe D,, Moller B,, Feucht HH,, Wiedenmann B,, Berg T. 2006. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 44:318325.
98. McMahon MA,, Jilek BL,, Brennan TP,, Shen L,, Zhou Y,, Wind-Rotolo M,, Xing S,, Bhat S,, Hale B,, Hegarty R,, Chong CR,, Liu JO,, Siliciano RF,, Thio CL. 2007. The HBV drug entecavir—effects on HIV-1 replication and resistance. N Engl J Med 356:26142621.
99. Jain MK,, Comanor L,, White C,, Kipnis P,, Elkin C,, Leung K,, Ocampo A,, Attar N,, Keiser P,, Lee WM. 2007. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response. J Viral Hepat 14:176182.
100. Nash K. 2009. Telbivudine in the treatment of chronic hepatitis B. Adv Ther 26:155169.
101. Lau GK,, Piratvisuth T,, Luo KX,, Marcellin P,, Thongsawat S,, Cooksley G,, Gane E,, Fried MW,, Chow WC,, Paik SW,, Chang WY,, Berg T,, Flisiak R,, McCloud P,, Pluck N. 2005. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352:26822695.
102. Marcellin P,, Lau GK,, Bonino F,, Farci P,, Hadziyannis S,, Jin R,, Lu ZM,, Piratvisuth T,, Germanidis G,, Yurdaydin C,, Diago M,, Gurel S,, Lai MY,, Button P,, Pluck N. 2004. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351:12061217.
103. Akuta N,, Kumada H. 2005. Influence of hepatitis B virus genotypes on the response to antiviral therapies. J Antimicrob Chemother 55:139142.
104. Lok AS,, McMahon BJ. 2009. Chronic hepatitis B: update 2009. Hepatology 50:661662.
105. De Clercq E. 2004. Antiviral drugs in current clinical use. J Clin Virol 30:115133.
106. Ormrod D,, Scott LJ,, Perry CM. 2000. Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections. Drugs 59:839863.
107. Talarico CL,, Burnette TC,, Miller WH,, Smith SL,, Davis MG,, Stanat SC,, Ng TI,, He Z,, Coen DM,, Roizman B,, Biron KK. 1999. Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein. Antimicrob Agents Chemother 43:19411946.
108. Field HJ,, Vere Hodge RA. 2013. Recent developments in anti-herpesvirus drugs. Br Med Bull 106:213249.
109. Whitley RJ,, Gnann JWJr. 1992. Acyclovir: a decade later. N Engl J Med 327:782789.
110. Hazar V,, Kansoy S,, Kupesiz A,, Aksoylar S,, Kantar M,, Yesilipek A. 2004. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation. Bone Marrow Transplant 33:931935.
111. Reischig T,, Jindra P,, Mares J,, Cechura M,, Svecova M,, Hes O,, Opatrny K,Jr,, Treska V. 2005. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. Transplantation 79:317324.
112. Xiong X,, Smith JL,, Chen MS. 1997. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob Agents Chemother 41:594599.
113. Magee WC,, Hostetler KY,, Evans DH. 2005. Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob Agents Chemother 49:31533162.
114. Naesens L,, Lenaerts L,, Andrei G,, Snoeck R,, Van Beers D,, Holy A,, Balzarini J,, De Clercq E. 2005. Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob Agents Chemother 49:10101016.
115. Kuypers DR,, Vandooren AK,, Lerut E,, Evenepoel P,, Claes K,, Snoeck R,, Naesens L,, Vanrenterghem Y. 2005. Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am J Transplant 5:19972004.
116. Shehab N,, Sweet BV,, Hogikyan ND. 2005. Cidofovir for the treatment of recurrent respiratory papillomatosis: a review of the literature. Pharmacotherapy 25:977989.
117. Gallagher TQ,, Derkay CS. 2008. Recurrent respiratory papillomatosis: update 2008. Curr Opin Otolaryngol Head Neck Surg 16:536542.
118. Wolf DL,, Rodriguez CA,, Mucci M,, Ingrosso A,, Duncan BA,, Nickens DJ. 2003. Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis. J Clin Pharmacol 43:4351.
119. Cundy KC,, Petty BG,, Flaherty J,, Fisher PE,, Polis MA,, Wachsman M,, Lietman PS,, Lalezari JP,, Hitchcock MJ,, Jaffe HS. 1995. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 39:12471252.
120. Lietman PS. 1992. Clinical pharmacology: foscarnet. Am J Med 92:8S11S.
121. Chrisp P,, Clissold SP. 1991. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 41:104129.
122. Aweeka F,, Gambertoglio J,, Mills J,, Jacobson MA. 1989. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. Antimicrob Agents Chemother 33:742745.
123. Schwarz A,, Perez-Canto A. 1998. Nephrotoxicity of antiinfective drugs. Int J Clin Pharmacol Ther 36:164167.
124. Casper C,, Krantz EM,, Corey L,, Kuntz SR,, Wang J,, Selke S,, Hamilton S,, Huang ML,, Wald A. 2008. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis 198:2330.
125. Sun HY,, Wagener MM,, Singh N. 2008. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am J Transplant 8:21112118.
126. Torres-Madriz G,, Boucher HW. 2008. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 47:702711.
127. Cvetkovic RS,, Wellington K. 2005. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs 65:859878.
128. Curran M,, Noble S. 2001. Valganciclovir. Drugs 61: 11451150; discussion, 51–52.
129. Pescovitz MD,, Rabkin J,, Merion RM,, Paya CV,, Pirsch J,, Freeman RB,, O’Grady J,, Robinson C,, To Z,, Wren K,, Banken L,, Buhles W,, Brown F. 2000. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 44:28112815.
130. Wiltshire H,, Paya CV,, Pescovitz MD,, Humar A,, Dominguez E,, Washburn K,, Blumberg E,, Alexander B,, Freeman R,, Heaton N,, Zuideveld KP. 2005. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 79:14771483.
131. Vere Hodge RA,, Sutton D,, Boyd MR,, Harnden MR,, Jarvest RL. 1989. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. Antimicrob Agents Chemother 33:17651773.
132. Schmid-Wendtner MH,, Korting HC. 2004. Penciclovir cream—improved topical treatment for herpes simplex infections. Skin Pharmacol Physiol 17:214218.
133. Luber AD,, Flaherty JFJr. 1996. Famciclovir for treatment of herpesvirus infections. Ann Pharmacother 30:978985.
134. Earnshaw DL,, Bacon TH,, Darlison SJ,, Edmonds K,, Perkins RM,, Vere Hodge RA. 1992. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother 36:27472757.
135. Simpson D,, Lyseng-Williamson KA. 2006. Famciclovir: a review of its use in herpes zoster and genital and orolabial herpes. Drugs 66:23972416.
136. Bacon TH,, Levin MJ,, Leary JJ,, Sarisky RT,, Sutton D. 2003. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 16:114128.
137. Chilukuri S,, Rosen T. 2003. Management of acyclovir-resistant herpes simplex virus. Dermatol Clin 21:311320.
138. Pepose JS,, Margolis TP,, LaRussa P,, Pavan-Langston D. 2003. Ocular complications of smallpox vaccination. Am J Ophthalmol 136:343352.
139. Carmine AA,, Brogden RN,, Heel RC,, Speight TM,, Avery GS. 1982. Trifluridine: a review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections. Drugs 23:329353.
140. Katz DH,, Marcelletti JF,, Khalil MH,, Pope LE,, Katz LR. 1991. Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex. Proc Natl Acad Sci U S A 88:1082510829.
141. Trofe J,, Pote L,, Wade E,, Blumberg E,, Bloom RD. 2008. Maribavir: a novel antiviral agent with activity against cytomegalovirus. Ann Pharmacother 42:14471457.
142. Ma JD,, Nafziger AN,, Villano SA,, Gaedigk A,, Bertino JSJr. 2006. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother 50:11301135.
143. Marty FM,, Ljungman P,, Papanicolaou GA,, Winston DJ,, Chemaly RF,, Strasfeld L,, Young JA,, Rodriguez T,, Maertens J,, Schmitt M,, Einsele H,, Ferrant A,, Lipton JH,, Villano SA,, Chen H,, Boeckh M. 2011. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 11:284292.
144. Winston DJ,, Saliba F,, Blumberg E,, Abouljoud M,, Garcia-Diaz JB,, Goss JA,, Clough L,, Avery R,, Limaye AP,, Ericzon BG,, Navasa M,, Troisi RI,, Chen H,, Villano SA,, Uknis ME. 2012. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant 12:30213030.
145. Price NB,, Prichard MN. 2011. Progress in the development of new therapies for herpesvirus infections. Curr Opin Virol 1:548554.
146. Avery RK,, Bolwell BJ,, Yen-Lieberman B,, Lurain N,, Waldman WJ,, Longworth DL,, Taege AJ,, Mossad SB,, Kohn D,, Long JR,, Curtis J,, Kalaycio M,, Pohlman B,, Williams JW. 2004. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant 34:10711075.
147. Levi ME,, Mandava N,, Chan LK,, Weinberg A,, Olson JL. 2006. Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. Transpl Infect Dis 8:3843.
148. Efferth T,, Romero MR,, Wolf DG,, Stamminger T,, Marin JJ,, Marschall M. 2008. The antiviral activities of artemisinin and artesunate. Clin Infect Dis 47:804811.
149. Shapira MY,, Resnick IB,, Chou S,, Neumann AU,, Lurain NS,, Stamminger T,, Caplan O,, Saleh N,, Efferth T,, Marschall M,, Wolf DG. 2008. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis 46:14551457.
150. Monto AS. 2003. The role of antivirals in the control of influenza. Vaccine 21:17961800.
151. Oxford JS. 2007. Antivirals for the treatment and prevention of epidemic and pandemic influenza. Influenza Other Respir Viruses 1:2734.
152. American Academy of Pediatrics Committee on Infectious Diseases. 2007. Antiviral therapy and prophylaxis for influenza in children. Pediatrics 119:852860.
153. Mould JA,, Drury JE,, Frings SM,, Kaupp UB,, Pekosz A,, Lamb RA,, Pinto LH. 2000. Permeation and activation of the M2 ion channel of influenza A virus. J Biol Chem 275:3103831050.
154. Jing X,, Ma C,, Ohigashi Y,, Oliveira FA,, Jardetzky TS,, Pinto LH,, Lamb RA. 2008. Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel. Proc Natl Acad Sci U S A 105:1096710972.
155. Monto AS,, Ohmit SE,, Hornbuckle K,, Pearce CL. 1995. Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrob Agents Chemother 39:22242228.
156. Suzuki Y,, Saito R,, Zaraket H,, Dapat C,, Caperig-Dapat I,, Suzuki H. 2010. Rapid and specific detection of amantadine-resistant influenza A viruses with a Ser31Asn mutation by the cycling probe method. J Clin Microbiol 48:5763.
157. Hurt AC,, Holien JK,, Parker MW,, Barr IG. 2009. Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. Drugs 69:25232531.
158. Dreitlein WB,, Maratos J,, Brocavich J. 2001. Zanamivir and oseltamivir: two new options for the treatment and prevention of influenza. Clin Ther 23:327355.
159. Cheng PK,, To AP,, Leung TW,, Leung PC,, Lee CW,, Lim WW. 2010. Oseltamivir- and amantadine-resistant influenza virus A (H1N1). Emerg Infect Dis 16:155156.
160. Leung TW,, Tai AL,, Cheng PK,, Kong MS,, Lim W. 2009. Detection of an oseltamivir-resistant pandemic influenza A/H1N1 virus in Hong Kong. J Clin Virol 46:298299.
161. Fiore AE,, Fry A,, Shay D,, Gubareva L,, Bresee JS,, Uyeki TM. 2011. Antiviral agents for the treatment and chemoprophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommend Rep 60:124.
162. Hill G,, Cihlar T,, Oo C,, Ho ES,, Prior K,, Wiltshire H,, Barrett J,, Liu B,, Ward P. 2002. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos 30:1319.
163. Bowles SK,, Lee W,, Simor AE,, Vearncombe M,, Loeb M,, Tamblyn S,, Fearon M,, Li Y,, McGeer A. 2002. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999–2000. J Am Geriatr Soc 50:608616.
164. Hayden FG,, Belshe R,, Villanueva C,, Lanno R,, Hughes C,, Small I,, Dutkowski R,, Ward P,, Carr J. 2004. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 189:440449.
165. Whitley RJ. 2007. The role of oseltamivir in the treatment and prevention of influenza in children. Expert Opin Drug Metab Toxicol 3:755767.
166. Calfee DP,, Hayden FG. 1998. New approaches to influenza chemotherapy. Neuraminidase inhibitors. Drugs 56:537553.
167. Ison MG,, Gnann JWJr,, Nagy-Agren S,, Treannor J,, Paya C,, Steigbigel R,, Elliott M,, Weiss HL,, Hayden FG. 2003. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 8:183190.
168. Cass LM,, Efthymiopoulos C,, Bye A. 1999. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 36(Suppl 1):111.

Tables

Generic image for table
TABLE 1

Antiviral agents for HIV therapy

Citation: Hodowanec A, Thompson K, Lurain N. 2015. Antiviral Agents, p 1869-1893. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of Clinical Microbiology, Eleventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817381.ch110
Generic image for table
TABLE 2

Antiviral agents for HCV therapy

Citation: Hodowanec A, Thompson K, Lurain N. 2015. Antiviral Agents, p 1869-1893. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of Clinical Microbiology, Eleventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817381.ch110
Generic image for table
TABLE 3

Antiviral agents for HBV therapy

Citation: Hodowanec A, Thompson K, Lurain N. 2015. Antiviral Agents, p 1869-1893. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of Clinical Microbiology, Eleventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817381.ch110
Generic image for table
TABLE 4

Antiviral agents for herpesviruses

Citation: Hodowanec A, Thompson K, Lurain N. 2015. Antiviral Agents, p 1869-1893. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of Clinical Microbiology, Eleventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817381.ch110
Generic image for table
TABLE 5

Antiviral agents for influenza virus

Citation: Hodowanec A, Thompson K, Lurain N. 2015. Antiviral Agents, p 1869-1893. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of Clinical Microbiology, Eleventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817381.ch110

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error